Overview
Pulmonary lymphangioleiomyomatosis (LAM) is a rare lung disease characterized by the proliferation of smooth muscle cells leading to lung cyst formation, primarily affecting women, often associated with tuberous sclerosis complex (TSC) 1.Diagnosis
Clinical Presentation: Recurrent pneumothorax, chylous pleural effusions, progressive dyspnea 41.
Imaging: High-resolution CT showing characteristic cystic changes 1.
Functional Tests: Spirometry often reveals restrictive pattern with reduced lung volumes 1.
Biopsy: Transbronchial lung biopsy can confirm diagnosis in some cases 8.
Serological Tests: Not typically diagnostic but may rule out other conditions 1.
Genetic Testing: Consider TSC gene mutations if clinical suspicion is high 1.Management
First-Line Treatments:
- Sirolimus: Target blood concentration 3.0-5.0 ng/mL 3.
- Oophorectomy: In premenopausal women to reduce estrogen dependency 10.
Adjunctive Treatments:
- Immunotherapy: Feasibility of vaccines targeting melanoma-associated antigens explored 5.
- Tacrolimus: Used in lung transplant patients for immunosuppression, with careful monitoring due to drug interactions 3.
Management of Complications:
- Recurrent Pneumothorax: Surgical interventions like pleurectomy may be necessary 10.
- Haemopericardium/Cardiac Tamponade: Emergency surgical decompression, e.g., subdiaphragmatic extraperitoneal window 9.Special Populations
Pregnancy: Not specifically addressed in abstracts provided 16.
Pediatrics: Limited data; primarily adult women affected 16.
Elderly: Management similar to younger adults, focusing on symptom control and complications 1.
Comorbidities: Management of LAM in transplant patients requires careful polypharmacy monitoring 3.Key Recommendations
Suspect LAM in young women with recurrent pneumothoraces or cystic lung changes on imaging (Evidence: Strong 1).
Consider sirolimus for treatment with therapeutic drug monitoring (Evidence: Moderate 3).
Evaluate for oophorectomy in premenopausal women to manage disease progression (Evidence: Expert opinion 10).
Monitor and manage drug interactions in LAM patients on multiple immunosuppressive agents (Evidence: Moderate 3).
Promptly address complications such as pneumothorax and cardiac tamponade with appropriate surgical interventions (Evidence: Weak 910).References
1 Cottin V, Blanchard E, Kerjouan M, Lazor R, Reynaud-Gaubert M, Taille C et al.. French recommendations for the diagnosis and management of lymphangioleiomyomatosis. Respiratory medicine and research 2023. link
2 Yang B, Moss J. Cell survival pathways targeted in rare lung disease affecting women. Science advances 2023. link
3 Kumondai M, Kikuchi M, Mizuguchi A, Hayashi N, Ui M, Hirama T et al.. Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors. The Tohoku journal of experimental medicine 2023. link
4 Chakrabarti N, Saha M, Basu B. Pulmonary lymphangioleiomyomatosis--a silent killer?. The Journal of the Association of Physicians of India 2012. link
5 Carbone M. Feasibility of immunotherapy for lymphangioleiomyomatosis. The American journal of pathology 2009. link
6 Pollock-BarZiv SM, Cohen MM, Maclean H, Downey GP. Canadian respirologists' experience with lymphangioleiomyomatosis. Canadian respiratory journal 2002. link
7 Dormans TP, Verrips A, Bulten J, Cox N. Pulmonary lymphangioleiomyomatosis and cerebrotendinous xanthomatosis: is there a link?. Chest 1997. link
8 Delgrange E, Delgrange B, Wallon J, Rosoux P. Diagnostic approach to pulmonary lymphangioleiomyomatosis. Journal of internal medicine 1994. link
9 Fahy J, Toner M, O'Sullivan J, FitzGerald MX. Haemopericardium and cardiac tamponade complicating pulmonary lymphangioleiomyomatosis. Thorax 1991. link
10 Logan RF, Fawcett IW. Oophorectomy for pulmonary lymphangioleiomyomatosis: a case report. British journal of diseases of the chest 1985. link90013-0)